Patent classifications
A61P27/08
METHODS AND COMPOSITIONS FOR TREATMENT OF MYDRIASIS
The invention provides methods, compositions, and kits containing an alpha-adrenergic antagonist, such as phentolamine, for use in monotherapy or as part of a combination therapy to treat patients suffering from presbyopia, mydriasis, and/or other ocular disorders.
METHODS AND COMPOSITIONS FOR TREATMENT OF MYDRIASIS
The invention provides methods, compositions, and kits containing an alpha-adrenergic antagonist, such as phentolamine, for use in monotherapy or as part of a combination therapy to treat patients suffering from presbyopia, mydriasis, and/or other ocular disorders.
Dissolvable medical device for drugs delivery
A dissolvable medical device for placing on the outer exposed surface of the eye to deliver a drug to the eye comprises: a polymeric film has sufficient dimensions to cover a cornea when applied to an eye and the polymeric film comprising one or more mucoadhesive polymers. The polymeric film dissolves between 15 minutes to 120 minutes to release the mucoadhesive and the pharmaceutically active agents after applying the polymeric film to the eye. The dissolved polymeric film is not impeding visualization of ocular tissue while maintaining a protective film on outer surface of the eye.
Dissolvable medical device for drugs delivery
A dissolvable medical device for placing on the outer exposed surface of the eye to deliver a drug to the eye comprises: a polymeric film has sufficient dimensions to cover a cornea when applied to an eye and the polymeric film comprising one or more mucoadhesive polymers. The polymeric film dissolves between 15 minutes to 120 minutes to release the mucoadhesive and the pharmaceutically active agents after applying the polymeric film to the eye. The dissolved polymeric film is not impeding visualization of ocular tissue while maintaining a protective film on outer surface of the eye.
Composition based on gellan gum and phenylephrine, production method and use as an ophthalmic product
The invention relates to a specific composition comprising in particular at least gellan gum and phenylephrine. It also relates to a particular method for manufacturing such a composition and its uses in particular as a mydriatic ophthalmic product.
Composition based on gellan gum and phenylephrine, production method and use as an ophthalmic product
The invention relates to a specific composition comprising in particular at least gellan gum and phenylephrine. It also relates to a particular method for manufacturing such a composition and its uses in particular as a mydriatic ophthalmic product.
Methods and compositions for treatment of mydriasis
The invention provides methods, compositions, and kits containing an alpha-adrenergic antagonist, such as phentolamine, for use in monotherapy or as part of a combination therapy to treat patients suffering from presbyopia, mydriasis, and/or other ocular disorders.
Methods and compositions for treatment of mydriasis
The invention provides methods, compositions, and kits containing an alpha-adrenergic antagonist, such as phentolamine, for use in monotherapy or as part of a combination therapy to treat patients suffering from presbyopia, mydriasis, and/or other ocular disorders.
Methods and compositions for treatment of mydriasis
The invention provides methods, compositions, and kits containing an alpha-adrenergic antagonist, such as phentolamine, for use in monotherapy or as part of a combination therapy to treat patients suffering from presbyopia, mydriasis, and/or other ocular disorders.
Methods and compositions for treatment of mydriasis
The invention provides methods, compositions, and kits containing an alpha-adrenergic antagonist, such as phentolamine, for use in monotherapy or as part of a combination therapy to treat patients suffering from presbyopia, mydriasis, and/or other ocular disorders.